Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | F9 | P00740 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29312262 | 1.00 | TNKS (0.33) | TNKSTNKS2ALOX5F9L3MBTL1 | |
| SCHEMBL29312248 | 1.00 | TNKS (0.33) | TNKSTNKS2ALOX5F9L3MBTL1 | |
| SCHEMBL29312294 | 0.99 | TNKS (0.33) | TNKSTNKS2ALOX5F9L3MBTL1 | |
| SCHEMBL29312460 | 0.98 | PDK2 (0.33) | TNKSTNKS2ALOX5F9PDK2 | |
| SCHEMBL29312257 | 0.98 | TNKS (0.33) | TNKSTNKS2ALOX5F9L3MBTL1 | |
| SCHEMBL29312412 | 0.96 | PDK2 (0.34) | TNKSTNKS2ALOX5F9L3MBTL1 | |
| SCHEMBL29312295 | 0.95 | TNKS (0.32) | TNKSTNKS2ALOX5 | |
| SCHEMBL29312413 | 0.95 | PDK2 (0.34) | TNKSTNKS2ALOX5F9L3MBTL1 | |
| SCHEMBL29312268 | 0.94 | F9 (0.34) | TNKSTNKS2ALOX5F9 | |
| SCHEMBL29312468 | 0.94 | PDK2 (0.31) | TNKSTNKS2ALOX5PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12041848-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-12041848-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12041848-B2 | Heterocyclic compound and organic light emitting element comprising same | CRY1, CRY2, NR2E3 | TNKS 3740/4885TNKS2 3550/4885ALOX5 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.